Nothing Special   »   [go: up one dir, main page]

HK1210706A1 - 可吸入藥物組合物 - Google Patents

可吸入藥物組合物

Info

Publication number
HK1210706A1
HK1210706A1 HK15111545.0A HK15111545A HK1210706A1 HK 1210706 A1 HK1210706 A1 HK 1210706A1 HK 15111545 A HK15111545 A HK 15111545A HK 1210706 A1 HK1210706 A1 HK 1210706A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
inhalable pharmaceutical
inhalable
compositions
pharmaceutical
Prior art date
Application number
HK15111545.0A
Other languages
English (en)
Inventor
．威廉．博施
馬修．卡拉漢
菲利克斯．梅斯特
馬克．諾雷特
艾德裡安．拉塞爾
Original Assignee
Iceutica Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Holdings Inc filed Critical Iceutica Holdings Inc
Publication of HK1210706A1 publication Critical patent/HK1210706A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15111545.0A 2012-02-28 2015-11-23 可吸入藥物組合物 HK1210706A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604435P 2012-02-28 2012-02-28
PCT/IB2013/000708 WO2013128283A2 (en) 2012-02-28 2013-02-28 Inhalable pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1210706A1 true HK1210706A1 (zh) 2016-05-06

Family

ID=48628732

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18112279.7A HK1252926A1 (zh) 2012-02-28 2015-11-23 可吸入藥物組合物
HK15111545.0A HK1210706A1 (zh) 2012-02-28 2015-11-23 可吸入藥物組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18112279.7A HK1252926A1 (zh) 2012-02-28 2015-11-23 可吸入藥物組合物

Country Status (14)

Country Link
US (2) US10022303B2 (zh)
EP (1) EP2819645A2 (zh)
JP (1) JP6231022B2 (zh)
KR (2) KR20150041608A (zh)
CN (2) CN104703584B (zh)
AU (3) AU2013227351B2 (zh)
CA (1) CA2865702C (zh)
HK (2) HK1252926A1 (zh)
IL (1) IL234365B (zh)
NZ (2) NZ629438A (zh)
RU (2) RU2697862C2 (zh)
SG (2) SG11201405243TA (zh)
WO (1) WO2013128283A2 (zh)
ZA (1) ZA201703992B (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877871C (en) 2012-06-25 2022-12-06 Gecko Health Innovations, Inc. Devices, systems, and methods for adherence monitoring and patient interaction
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2991634A1 (en) 2013-04-30 2016-03-09 Otitopic Inc. Dry powder formulations and methods of use
JP6509864B2 (ja) 2013-08-28 2019-05-08 ゲッコー ヘルス イノベーションズ インコーポレイテッド アドヒアランス監視用のデバイス、システム、方法および消耗品用のディスペンサの使用監視用のデバイス、システム、方法
JP2017510624A (ja) 2014-02-10 2017-04-13 パタラ ファーマ リミテッド ライアビリティ カンパニー 肥満細胞安定剤による全身性障害の治療
US20160367520A1 (en) 2014-02-10 2016-12-22 Patara Pharma, LLC Mast cell stabilizers for lung disease treatment
EP3107548B8 (en) 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same
JP6730937B2 (ja) * 2014-06-06 2020-07-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 免疫療法のための抗原負荷キトサンナノ粒子
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
CA2951690A1 (en) 2014-06-09 2015-12-17 Biometry Inc. Low cost test strip and method to measure analyte
DK3179986T3 (da) * 2014-07-31 2023-05-01 Vectura Inc Tørpulverformuleringer til inhalation
EP3212212B1 (en) 2014-10-31 2020-09-23 Monash University Powder formulation
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
US11723864B2 (en) 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
RU2732480C2 (ru) * 2015-06-30 2020-09-17 Сосьете Де Продюи Нестле С.А. Композиция, подходящая для защиты микроорганизмов
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
KR101880295B1 (ko) * 2016-01-12 2018-08-02 주식회사 시너지이노베이션 디히드로에르고타민 타트레이트를 포함하는 폐암의 예방 또는 치료용 조성물
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
JP2019519489A (ja) * 2016-05-05 2019-07-11 リクイディア・テクノロジーズ・インコーポレーテッド 肺高血圧症を治療するための乾燥粉末トレプロスチニル
WO2018017699A1 (en) 2016-07-19 2018-01-25 Nolan Bryan Methods of and systems for measuring analytes using batch calibratable test strips
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018047013A1 (en) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
WO2018047002A1 (en) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
US10786456B2 (en) * 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US10195147B1 (en) * 2017-09-22 2019-02-05 Otitopic Inc. Dry powder compositions with magnesium stearate
CA3084182A1 (en) * 2018-02-01 2019-08-08 Corvus Pharmaceuticals, Inc. Pharmaceutical formulations
EP3749298B1 (en) 2018-02-07 2023-04-05 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
WO2019171174A2 (en) 2018-03-07 2019-09-12 St Ip Holding Ag Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
IT201800006909A1 (it) * 2018-07-04 2020-01-04 Polvere secca di ambroxolo per uso inalatorio con target bronchiale
WO2020031119A1 (en) * 2018-08-07 2020-02-13 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
CN113166127A (zh) 2018-09-18 2021-07-23 St知识产权控股公司 4-烷基-5-杂芳基-3h-1,2-二硫杂环戊烯-3-硫酮的旋转异构异构体
EP3673895A1 (en) 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
US11499904B2 (en) * 2020-02-12 2022-11-15 National Guard Health Affairs In vitro dissolution test method for fluticasone propionate and other inhaled drugs
WO2021186244A1 (en) 2020-03-16 2021-09-23 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
JP2023539073A (ja) 2020-08-14 2023-09-13 ノートン （ウォーターフォード） リミテッド プロピオン酸フルチカゾンと硫酸アルブテロールの吸入製剤
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
KR102488719B1 (ko) * 2020-12-03 2023-01-13 충북대학교 산학협력단 셀레시파그를 함유하는 건조 분말 흡입 제제 및 그 제조방법
KR20230039894A (ko) * 2021-09-14 2023-03-22 한국유나이티드제약 주식회사 코로나 19 바이러스 감염 질환의 예방 또는 치료를 위한 흡입형 약학조성물
WO2023105086A1 (en) * 2021-12-10 2023-06-15 Gudiminchi Rama Krishna Use of glycosylated sugar alcohols
WO2023247952A1 (en) * 2022-06-21 2023-12-28 Hovione Scientia Limited Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture
WO2024009079A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1084994B (it) * 1976-06-09 1985-05-28 Funk Heporaut Kirsti Guarnizione per alberi,in particolare in mulini con agiotatore oppure in mulini colloidali
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
AU755066B2 (en) * 1998-04-18 2002-12-05 Glaxo Group Limited Pharmaceutical aerosol formulation
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
DE60137943D1 (de) * 2000-08-31 2009-04-23 Jagotec Ag Gemahlene partikel
DK1920763T3 (da) * 2000-11-30 2014-07-07 Vectura Ltd Farrmaceutiske præparater til inhalation
AU2002330390A1 (en) * 2002-03-20 2003-09-29 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
WO2008013938A2 (en) 2006-07-27 2008-01-31 Nektar Therapeutics Aerosolizable formulation comprising insulin for pulmonary delivery
GB0721394D0 (en) 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
CN108434126B (zh) 2009-03-26 2021-11-19 普马特里克斯营业公司 治疗肺病的干粉配方与方法
KR20120088547A (ko) 2009-04-24 2012-08-08 아이슈티카 피티와이 리미티드 상용 나노입자 및 미립자 분말의 제조방법
AU2009100698B4 (en) 2009-07-17 2010-04-15 Astrazeneca Ab Combination
EP2512439B1 (en) * 2009-12-14 2016-08-24 Chiesi Farmaceutici S.p.A. Antibiotic microparticles for inhalation

Also Published As

Publication number Publication date
KR20150041608A (ko) 2015-04-16
CN104703584B (zh) 2019-05-31
SG11201405243TA (en) 2014-09-26
CN104703584A (zh) 2015-06-10
SG10201703243QA (en) 2017-06-29
AU2013227351B2 (en) 2016-06-16
RU2019110128A (ru) 2019-05-08
ZA201703992B (en) 2019-12-18
AU2017213466A1 (en) 2017-08-31
NZ629438A (en) 2016-10-28
EP2819645A2 (en) 2015-01-07
RU2697862C2 (ru) 2019-08-21
KR20200015828A (ko) 2020-02-12
RU2014139046A (ru) 2016-04-20
IL234365B (en) 2019-09-26
JP2015508808A (ja) 2015-03-23
US10022303B2 (en) 2018-07-17
NZ722952A (en) 2018-12-21
RU2019110128A3 (zh) 2020-06-04
US20180318170A1 (en) 2018-11-08
CA2865702C (en) 2020-04-28
JP6231022B2 (ja) 2017-11-15
WO2013128283A2 (en) 2013-09-06
HK1252926A1 (zh) 2019-06-06
AU2017213466B2 (en) 2019-03-14
AU2013227351A1 (en) 2014-09-18
CA2865702A1 (en) 2013-09-06
AU2016202881A1 (en) 2016-05-26
CN107875127A (zh) 2018-04-06
WO2013128283A3 (en) 2013-10-31
US20140065219A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
IL230010B (en) Inhalable pharmaceutical ingredients
HK1209638A1 (zh) 藥物組合物
GB201113662D0 (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
AP3656A (en) Pharmaceutical compositions
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1199821A1 (zh) 口服用醫藥組合物
HK1199822A1 (zh) 口服給藥用醫藥組合物
GB201118181D0 (en) Pharmaceutical compositions
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
EP2714715A4 (en) PHARMACEUTICAL COMPOSITIONS
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition